We recently reported that people with type 2 diabetes using insulin were at an increased risk of a combined endpoint defined as first major adverse cardiac event, first cancer, or mortality, with the risk being significantly higher for users of insulin monotherapy compared with users of insulin plus concomitant metformin [18]. This evidence concerns the gene INS and type 2 diabetes mellitus.